Lapatinib Tablets 250 mg
LAPALIEVA 250 MG (Lapatinib Tablets 250 mg) is a targeted anticancer medicine used in the treatment of certain types of HER2-positive breast cancer. It contains Lapatinib, an advanced tyrosine kinase inhibitor (TKI) that works by blocking specific proteins responsible for the growth and spread of cancer cells. This targeted therapy is widely prescribed by oncologists for patients with advanced, metastatic, or treatment-resistant breast cancer.
Breast cancer remains one of the most commonly diagnosed cancers worldwide. In some patients, cancer cells produce excessive amounts of a protein known as Human Epidermal Growth Factor Receptor 2 (HER2). This protein promotes rapid cancer cell growth and increases the aggressiveness of the disease. LAPALIEVA 250 MG helps control this process by targeting HER2 and Epidermal Growth Factor Receptor (EGFR), thereby slowing cancer progression and supporting long-term disease management.
Unlike traditional chemotherapy, Lapatinib specifically targets cancer-related pathways, making it an important component of modern precision oncology treatment. It is often used in combination with other anticancer medicines to improve treatment outcomes and help patients achieve better disease control.
LAPALIEVA 250 MG is commonly prescribed for:
• HER2-positive metastatic breast cancer
• Advanced breast cancer
• Hormone receptor-positive and HER2-positive breast cancer
• Recurrent breast cancer
• Combination targeted therapy protocols
• Long-term oncology treatment programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and cancer treatment.
Patients receiving LAPALIEVA 250 MG may require regular medical monitoring, imaging studies, liver function assessments, and cardiac evaluations throughout therapy. These assessments help doctors evaluate treatment effectiveness and identify any potential complications early.
Because of its proven effectiveness in HER2-positive breast cancer treatment, LAPALIEVA 250 MG has become an important part of modern targeted cancer therapy and personalized oncology care.
View Details
Sorafenib Tablets 200mg
SORALIEVA 200MG (Sorafenib Tablets 200mg) is a targeted anticancer medicine used in the treatment of specific types of liver cancer, kidney cancer, and thyroid cancer. It contains Sorafenib Tosylate, a multikinase inhibitor that helps slow the growth and spread of cancer cells by blocking certain proteins and signaling pathways involved in tumor development and blood vessel formation.
Cancer cells require a constant supply of nutrients and oxygen to grow and spread. Sorafenib works by targeting multiple kinases involved in cancer cell proliferation and angiogenesis (the formation of new blood vessels that feed tumors). By blocking these pathways, SORALIEVA 200MG helps reduce tumor growth and may slow disease progression in eligible patients.
Unlike conventional chemotherapy, Sorafenib is a targeted therapy designed to interfere with specific molecular mechanisms that support cancer growth. This approach makes it an important treatment option in modern oncology, especially for patients with advanced or metastatic cancers.
SORALIEVA 200MG is commonly prescribed for:
• Hepatocellular Carcinoma (HCC) – Liver Cancer
• Advanced Renal Cell Carcinoma (RCC) – Kidney Cancer
• Differentiated Thyroid Carcinoma (DTC)
• Advanced or Metastatic Solid Tumors
• Long-Term Targeted Cancer Therapy Programs
The medicine is often recommended when surgery or other treatment options are not suitable, or when cancer has progressed despite previous therapies.
Manufactured under stringent pharmaceutical quality standards, SORALIEVA 200MG is designed to provide reliable therapeutic performance and consistent quality. It should only be used under the supervision of qualified oncologists or healthcare professionals experienced in cancer treatment.
Patients undergoing treatment with Sorafenib may require regular blood tests, liver function monitoring, blood pressure assessments, and imaging studies to evaluate treatment effectiveness and manage potential side effects.
Due to its effectiveness in advanced cancer management, SORALIEVA 200MG has become an important component of modern targeted oncology treatment protocols worldwide.
View Details
Axitinib Tablets 5 mg
AXILIEVA 5MG (Axitinib Tablets 5 mg) is a targeted anticancer medicine used in the treatment of advanced kidney cancer (Renal Cell Carcinoma) and certain other oncology indications as prescribed by healthcare professionals. It contains Axitinib, a potent vascular endothelial growth factor receptor (VEGFR) inhibitor that helps slow the growth and spread of cancer cells by reducing the formation of new blood vessels that tumors need to survive and grow.
Cancer cells depend on a steady blood supply to receive oxygen and nutrients. Axitinib works by blocking specific receptors involved in angiogenesis, the process through which tumors create new blood vessels. By inhibiting these pathways, AXILIEVA 5MG helps restrict tumor growth and may contribute to better disease control in eligible patients.
Unlike conventional chemotherapy, Axitinib is a targeted therapy that focuses on molecular pathways associated with cancer progression. This precision-based approach allows oncologists to manage certain cancers more effectively while supporting individualized treatment strategies.
AXILIEVA 5MG is commonly prescribed for:
• Advanced Renal Cell Carcinoma (RCC)
• Metastatic Kidney Cancer
• Targeted Oncology Treatment Programs
• Combination Immunotherapy Protocols
• Long-Term Cancer Management
• Advanced Solid Tumor Treatment Under Specialist Guidance
The medicine may be used alone or in combination with other anticancer therapies depending on the patient’s diagnosis, treatment history, and overall health condition.
Manufactured under stringent pharmaceutical quality standards, AXILIEVA 5MG is designed to deliver reliable therapeutic performance and consistent product quality. The medicine should only be used under the supervision of qualified oncologists and healthcare professionals experienced in cancer treatment.
Patients receiving Axitinib therapy may require regular monitoring of blood pressure, liver function, kidney function, thyroid function, and overall treatment response. These evaluations help optimize treatment outcomes and manage potential side effects effectively.
Due to its effectiveness in targeted oncology care, AXILIEVA 5MG has become an important component of modern kidney cancer treatment protocols and precision cancer therapy programs.
View Details
Hydroxyurea Capsules IP 500mg
HYDLIEVA 500MG (Hydroxyurea Capsules IP 500mg) is a prescription medicine used in the treatment of certain blood disorders and cancers. It contains Hydroxyurea 500mg, a well-established antimetabolite medication that works by slowing the growth and multiplication of abnormal cells in the body. Hydroxyurea is widely prescribed by hematologists and oncologists for managing conditions such as chronic myeloid leukemia, sickle cell disease, and other myeloproliferative disorders.
HYDLIEVA 500MG plays an important role in modern hematology and oncology treatment because it helps control excessive blood cell production and reduces disease-related complications. The medicine works by interfering with DNA synthesis, which slows down the growth of rapidly dividing cells. This mechanism makes Hydroxyurea effective in managing both cancerous and non-cancerous blood disorders.
Patients with blood-related conditions often require long-term treatment and careful monitoring. HYDLIEVA 500MG helps improve disease control, reduce complications, and support overall quality of life when used under appropriate medical supervision.
This medicine is commonly prescribed for:
• Chronic Myeloid Leukemia (CML)
• Sickle Cell Disease
• Polycythemia Vera
• Essential Thrombocythemia
• Certain Myeloproliferative Disorders
• Blood Cell Production Disorders
• Hematology and Oncology Treatment Programs
Hydroxyurea has been widely used for many years and remains an important treatment option in specialized blood disorder management. It is particularly valuable in sickle cell disease, where it helps reduce painful crises and improve overall disease outcomes.
HYDLIEVA 500MG is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. The medicine should only be used under the supervision of qualified healthcare professionals.
Patients receiving Hydroxyurea therapy may require regular blood tests, kidney function monitoring, liver function assessments, and medical evaluations throughout treatment. These assessments help ensure treatment effectiveness and identify potential side effects early.
Due to its proven effectiveness in hematology and oncology care, HYDLIEVA 500MG remains an important medicine in modern blood disorder treatment programs.
View Details
Bicalutamide Tablet IP 50mg
BICALIEVA 50MG (Bicalutamide Tablet IP 50mg) is a prescription anti-cancer medicine used in the treatment and management of prostate cancer. It contains Bicalutamide 50mg, a non-steroidal antiandrogen that works by blocking the effects of male hormones (androgens), particularly testosterone, which can stimulate the growth of prostate cancer cells.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells rely on testosterone and other androgens to grow and multiply. BICALIEVA 50MG helps control the disease by preventing these hormones from attaching to cancer cells, thereby slowing cancer growth and reducing tumor progression.
Bicalutamide is widely used as part of hormone therapy for prostate cancer and is often prescribed in combination with other treatments such as luteinizing hormone-releasing hormone (LHRH) agonists or surgical castration. This combined approach helps achieve more effective androgen deprivation, which is an important strategy in prostate cancer management.
BICALIEVA 50MG is commonly prescribed for:
• Advanced Prostate Cancer
• Metastatic Prostate Cancer
• Hormone-Sensitive Prostate Cancer
• Androgen Deprivation Therapy (ADT)
• Combination Prostate Cancer Treatment
• Long-Term Oncology and Urology Care
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and urology treatment.
Patients receiving BICALIEVA 50MG may require regular monitoring of prostate-specific antigen (PSA) levels, liver function, overall treatment response, and routine medical evaluations. These assessments help healthcare providers optimize treatment outcomes and manage potential side effects effectively.
Due to its proven role in hormone-based prostate cancer treatment, BICALIEVA 50MG remains an important medicine in modern oncology and urology care programs.
View Details
Letrozole Tablets IP 2.5 mg
LETROLIEVA 2.5 MG (Letrozole Tablets IP 2.5 mg) is a prescription medicine used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. It contains Letrozole 2.5 mg, a highly effective aromatase inhibitor that helps reduce estrogen levels in the body. Since certain breast cancers depend on estrogen for growth and survival, lowering estrogen levels can help slow or stop the growth of cancer cells.
Breast cancer is one of the most common cancers affecting women worldwide. In many cases, cancer cells possess hormone receptors that respond to estrogen. LETROLIEVA 2.5 MG works by blocking the aromatase enzyme, which is responsible for producing estrogen in postmenopausal women. By reducing estrogen production, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to grow.
Letrozole is widely used as part of modern hormone therapy and targeted breast cancer treatment programs. It may be prescribed after surgery, radiation therapy, chemotherapy, or as a long-term maintenance treatment to reduce the risk of cancer recurrence.
LETROLIEVA 2.5 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
In addition to its role in oncology, Letrozole may sometimes be prescribed for fertility-related conditions under specialist supervision. However, its primary use remains breast cancer treatment and management.
Manufactured under stringent pharmaceutical quality standards, LETROLIEVA 2.5 MG is designed to provide consistent therapeutic performance and reliable treatment outcomes. The medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormone therapy.
Patients receiving Letrozole therapy may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure safe and effective treatment.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease control, LETROLIEVA 2.5 MG has become an essential medicine in modern breast cancer care.
View Details
Anastrozole Tablets 1 mg
ANALIEVA 1 MG (Anastrozole Tablets 1 mg) is a prescription hormone therapy medicine used for the treatment and management of hormone receptor-positive breast cancer in postmenopausal women. It contains Anastrozole 1 mg, a highly effective aromatase inhibitor that helps reduce estrogen production in the body. Since many breast cancers depend on estrogen to grow and spread, lowering estrogen levels can help slow cancer progression and reduce the risk of recurrence.
Breast cancer is one of the most common cancers affecting women globally. In hormone receptor-positive breast cancer, cancer cells use estrogen as a growth signal. ANALIEVA 1 MG works by blocking the aromatase enzyme, which is responsible for converting androgens into estrogen in postmenopausal women. By significantly reducing estrogen levels, the medicine helps prevent cancer cells from receiving the hormonal stimulation they need to survive and multiply.
Anastrozole has become an important part of modern breast cancer treatment protocols and is widely recommended by oncologists for both early-stage and advanced hormone-sensitive breast cancer. It is often prescribed after surgery, radiation therapy, or chemotherapy to support long-term disease control and improve treatment outcomes.
ANALIEVA 1 MG is commonly prescribed for:
• Hormone Receptor-Positive Breast Cancer
• Early-Stage Breast Cancer
• Advanced Breast Cancer
• Metastatic Breast Cancer
• Adjuvant Hormonal Therapy
• Long-Term Breast Cancer Management
• Postmenopausal Breast Cancer Treatment
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, efficacy, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and hormonal cancer therapy.
Patients receiving ANALIEVA 1 MG may require regular medical monitoring, bone density assessments, cholesterol evaluations, and routine follow-up visits to ensure treatment effectiveness and manage potential side effects.
Due to its proven effectiveness in reducing breast cancer recurrence and supporting long-term disease management, ANALIEVA 1 MG remains an essential medicine in modern breast cancer care.
View Details
Nintedanib Softgelatin Capsules 150mg
NINDALIEVA 150 MG (Nintedanib Softgelatin Capsules 150 mg) is a prescription medicine used for the treatment of Idiopathic Pulmonary Fibrosis (IPF), Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), and certain other chronic lung conditions as prescribed by healthcare professionals. It contains Nintedanib 150 mg, a tyrosine kinase inhibitor that helps slow the progression of lung fibrosis by targeting multiple pathways involved in tissue scarring and abnormal cell growth.
Idiopathic Pulmonary Fibrosis is a serious chronic lung disease characterized by progressive scarring of lung tissue. Over time, this scarring reduces the lungs' ability to transfer oxygen into the bloodstream, making breathing increasingly difficult. NINDALIEVA 150 MG helps slow the rate of lung function decline, supporting long-term respiratory health and improving disease management.
Nintedanib works by blocking specific growth factor receptors involved in the formation of fibrotic tissue. By inhibiting these pathways, the medicine helps reduce excessive scar tissue development in the lungs and may delay disease progression in eligible patients.
In addition to pulmonary fibrosis, Nintedanib is also used in selected patients with other progressive interstitial lung diseases and may be prescribed as part of comprehensive respiratory care programs.
NINDALIEVA 150 MG is commonly prescribed for:
• Idiopathic Pulmonary Fibrosis (IPF)
• Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
• Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
• Chronic Progressive Lung Fibrosis
• Long-Term Pulmonary Disease Management
• Specialist Respiratory Care Programs
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in respiratory medicine.
Patients receiving Nintedanib therapy may require regular monitoring of liver function, lung function, overall treatment response, and routine medical assessments. These evaluations help healthcare providers optimize treatment outcomes and identify potential side effects early.
Due to its effectiveness in slowing disease progression and supporting long-term respiratory care, NINDALIEVA 150 MG has become an important treatment option in modern pulmonary medicine.
View Details
Imatinib Mesylate Tablets IP 400mg
IMALIEVA 400 MG (Imatinib Mesylate Tablets IP 400 mg) is a targeted anticancer medicine used for the treatment of certain blood cancers, gastrointestinal tumors, and other cancers driven by specific genetic abnormalities. It contains Imatinib Mesylate 400 mg, a tyrosine kinase inhibitor (TKI) that works by blocking abnormal proteins responsible for the growth and multiplication of cancer cells.
Imatinib revolutionized cancer treatment by becoming one of the first successful targeted therapies. Unlike conventional chemotherapy, which affects both healthy and cancerous cells, Imatinib specifically targets abnormal enzymes that contribute to cancer progression. This targeted approach helps slow disease progression, improve treatment outcomes, and support long-term cancer management.
IMALIEVA 400 MG is widely prescribed by oncologists and hematologists for patients diagnosed with specific cancers that contain abnormal tyrosine kinase activity. By targeting these cancer-driving proteins, the medicine helps control tumor growth and reduce the spread of disease.
This medicine is commonly used in the treatment of:
• Chronic Myeloid Leukemia (CML)
• Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
• Gastrointestinal Stromal Tumors (GIST)
• Myelodysplastic/Myeloproliferative Disorders (MDS/MPD)
• Hypereosinophilic Syndrome (HES)
• Dermatofibrosarcoma Protuberans (DFSP)
• Advanced Hematological and Solid Tumor Conditions
IMALIEVA 400 MG may be prescribed as a first-line treatment or as part of long-term cancer management programs depending on the patient's diagnosis, treatment history, and response to therapy.
The medicine is manufactured under strict pharmaceutical quality standards to ensure safety, effectiveness, and consistent therapeutic performance. It should only be used under the supervision of qualified healthcare professionals experienced in oncology and hematology care.
Patients receiving Imatinib therapy may require regular blood tests, liver function monitoring, kidney assessments, and periodic medical evaluations to ensure optimal treatment outcomes and early detection of potential side effects.
Due to its proven effectiveness in targeted cancer therapy, IMALIEVA 400 MG has become one of the most important medicines in modern oncology and hematology treatment programs worldwide.
View Details
Capecitabine Dispersible Tablets 500mg
CAPELIEVA-DT 500 MG (Capecitabine Dispersible Tablets 500 mg) is an oral chemotherapy medicine used in the treatment of various cancers, including colorectal cancer, breast cancer, and gastric cancer. It contains Capecitabine 500 mg, a fluoropyrimidine antineoplastic agent that is converted into its active form, 5-Fluorouracil (5-FU), within the body. This targeted conversion allows the medicine to interfere with cancer cell growth and multiplication while supporting effective cancer management.
Cancer cells grow and divide much faster than normal cells. Capecitabine works by disrupting DNA synthesis in rapidly dividing cells, preventing tumor growth and slowing the progression of cancer. Because the active medicine is produced in higher concentrations within tumor tissues, Capecitabine has become an important component of modern cancer treatment protocols.
CAPELIEVA-DT 500 MG is formulated as a dispersible tablet, offering greater convenience for patients who may have difficulty swallowing conventional tablets. The tablet can be dispersed according to the instructions provided by healthcare professionals, ensuring easier administration and better treatment compliance.
This medicine is widely prescribed by oncologists for patients diagnosed with:
• Colorectal Cancer
• Colon Cancer
• Rectal Cancer
• Metastatic Colorectal Cancer
• Breast Cancer
• Metastatic Breast Cancer
• Gastric (Stomach) Cancer
• Gastroesophageal Cancer
• Advanced Solid Tumors
• Combination Chemotherapy Programs
Capecitabine may be used alone or alongside other anticancer medicines depending on the patient's condition, cancer stage, and treatment goals. It is frequently included in personalized cancer treatment plans designed to improve outcomes and support long-term disease control.
Manufactured under stringent pharmaceutical quality standards, CAPELIEVA-DT 500 MG provides reliable therapeutic performance, safety, and consistency. The medicine should only be used under the supervision of qualified oncologists or healthcare professionals experienced in cancer care.
Patients receiving Capecitabine therapy often require regular blood tests, liver function monitoring, kidney assessments, and medical evaluations to ensure safe and effective treatment. These routine assessments help healthcare providers monitor treatment response and identify any potential side effects early.
Due to its proven effectiveness and convenience as an oral chemotherapy option, CAPELIEVA-DT 500 MG remains an important part of modern oncology treatment programs worldwide.
View Details
Irinotecan Hydrochloride Injection 100mg
IRILIEVA 100 MG (Irinotecan Hydrochloride Injection 100 mg) is a prescription anticancer medicine used in the treatment of various solid tumors, particularly colorectal cancer. It contains Irinotecan Hydrochloride 100 mg, a chemotherapy agent that belongs to the class of medicines known as topoisomerase I inhibitors. The medicine works by interfering with the DNA replication process of cancer cells, helping to slow or stop their growth and spread.
Cancer cells divide rapidly and continuously. Irinotecan targets these rapidly multiplying cells by blocking the activity of an enzyme called topoisomerase I, which is essential for DNA replication and cell division. As a result, cancer cells are unable to reproduce effectively and eventually die, helping to control tumor growth and disease progression.
IRILIEVA 100 MG is widely used in modern oncology treatment protocols and may be administered alone or in combination with other chemotherapy medicines. It plays a significant role in the treatment of advanced and metastatic cancers, particularly gastrointestinal malignancies.
This medicine is commonly prescribed for:
• Metastatic Colorectal Cancer
• Advanced Colon Cancer
• Rectal Cancer
• Gastrointestinal Cancers
• Combination Chemotherapy Protocols
• Advanced Solid Tumors
• Oncology Treatment Programs
• Long-Term Cancer Management
Irinotecan is often included in internationally recognized chemotherapy regimens and may be combined with other anticancer medicines to improve treatment effectiveness and patient outcomes.
Manufactured under stringent pharmaceutical quality standards, IRILIEVA 100 MG is designed to provide reliable therapeutic performance, safety, and consistency. The medicine should only be administered by qualified healthcare professionals in hospitals, oncology centers, or specialized treatment facilities.
Patients receiving Irinotecan therapy typically require regular blood tests, liver function monitoring, kidney assessments, and medical evaluations to ensure safe and effective treatment. These assessments help monitor treatment response and identify potential side effects at an early stage.
Due to its proven effectiveness in cancer treatment, IRILIEVA 100 MG remains an important component of modern chemotherapy and oncology care programs worldwide.
View Details
Zoledronic Acid Injection IP 4mg
ZODLIEVA 4 MG (Zoledronic Acid Injection IP 4 mg) is a prescription medicine used for the treatment and management of bone-related complications associated with cancer, osteoporosis, and other conditions that affect bone strength and calcium balance. It contains Zoledronic Acid 4 mg, a potent bisphosphonate that helps protect bones by slowing down excessive bone breakdown and reducing the risk of fractures.
Healthy bones constantly undergo a natural process of breakdown and rebuilding. In certain medical conditions such as cancer with bone metastases, multiple myeloma, osteoporosis, and hypercalcemia of malignancy, this balance becomes disrupted, causing bones to weaken and become more susceptible to fractures. ZODLIEVA 4 MG helps restore this balance by inhibiting the activity of osteoclasts, the cells responsible for bone resorption.
Zoledronic Acid is widely used in oncology and bone health management because it helps strengthen bones, reduce skeletal complications, and improve quality of life for patients with bone-related disorders. The medicine is administered intravenously under the supervision of healthcare professionals and is often included in comprehensive cancer care and osteoporosis treatment programs.
ZODLIEVA 4 MG is commonly prescribed for:
• Bone Metastases from Solid Tumors
• Multiple Myeloma
• Hypercalcemia of Malignancy
• Osteoporosis
• Cancer-Related Bone Disease
• Prevention of Skeletal-Related Events (SREs)
• Bone Loss Associated with Cancer Treatment
• Long-Term Bone Health Management
Patients with advanced cancers frequently develop bone complications such as fractures, bone pain, and elevated calcium levels. Zoledronic Acid helps reduce these risks and supports long-term skeletal health.
Manufactured under strict pharmaceutical quality standards, ZODLIEVA 4 MG is designed to provide reliable therapeutic performance, safety, and consistency. The medicine should only be administered by qualified healthcare professionals experienced in oncology, endocrinology, or bone health management.
Patients receiving Zoledronic Acid therapy may require regular monitoring of kidney function, calcium levels, vitamin D status, and overall treatment response to ensure safe and effective use.
Due to its proven effectiveness in reducing bone complications and preserving skeletal health, ZODLIEVA 4 MG remains an important treatment option in modern oncology and bone disease management.
View Details
